332 related articles for article (PubMed ID: 8168102)
21. Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation.
Reiter Y; Brinkmann U; Jung SH; Pastan I; Lee B
Protein Eng; 1995 Dec; 8(12):1323-31. PubMed ID: 8869646
[TBL] [Abstract][Full Text] [Related]
22. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
Kuan CT; Pastan I
Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123
[TBL] [Abstract][Full Text] [Related]
23. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
Hao HJ; Jiang YQ; Zheng YL; Ma R; Yu DW
Biochimie; 2005 Aug; 87(8):661-7. PubMed ID: 15927340
[TBL] [Abstract][Full Text] [Related]
24. Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts.
Choi CW; Lang L; Lee JT; Webber KO; Yoo TM; Chang HK; Le N; Jagoda E; Paik CH; Pastan I
Cancer Res; 1995 Nov; 55(22):5323-9. PubMed ID: 7585595
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A.
Onda M; Olafsen T; Tsutsumi Y; Bruland ØS ØS; Pastan I
J Immunother (1991); 2001 Mar; 24(2):144-150. PubMed ID: 11449071
[TBL] [Abstract][Full Text] [Related]
26. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.
Bera TK; Onda M; Brinkmann U; Pastan I
J Mol Biol; 1998 Aug; 281(3):475-83. PubMed ID: 9698563
[TBL] [Abstract][Full Text] [Related]
27. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin.
Kobayashi H; Kao CH; Kreitman RJ; Le N; Kim MK; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
J Nucl Med; 2000 Apr; 41(4):755-62. PubMed ID: 10768579
[TBL] [Abstract][Full Text] [Related]
29. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
30. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
[TBL] [Abstract][Full Text] [Related]
31. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
Benhar I; Pastan I
J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
[TBL] [Abstract][Full Text] [Related]
32. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo efficacy of a recombinant immunotoxin against folate receptor beta on the activation and proliferation of rheumatoid arthritis synovial cells.
Nagai T; Tanaka M; Tsuneyoshi Y; Matsushita K; Sunahara N; Matsuda T; Yoshida H; Komiya S; Onda M; Matsuyama T
Arthritis Rheum; 2006 Oct; 54(10):3126-34. PubMed ID: 17009233
[TBL] [Abstract][Full Text] [Related]
34. A divalent recombinant immunotoxin formed by a disulfide bond between the extension peptide chains.
Park JH; Kwon HW; Chung HK; Kim IH; Ahn K; Choi EJ; Pastan I; Choe M
Mol Cells; 2001 Dec; 12(3):398-402. PubMed ID: 11804341
[TBL] [Abstract][Full Text] [Related]
35. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
[TBL] [Abstract][Full Text] [Related]
36. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
Tsutsumi Y; Onda M; Nagata S; Lee B; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8548-53. PubMed ID: 10890891
[TBL] [Abstract][Full Text] [Related]
37. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
Onda M; Nagata S; Tsutsumi Y; Vincent JJ; Wang Q; Kreitman RJ; Lee B; Pastan I
Cancer Res; 2001 Jul; 61(13):5070-7. PubMed ID: 11431343
[TBL] [Abstract][Full Text] [Related]
38. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
